You Position: Home > Paper
Clinical advances on danoprevir and triple therapy of danoprevir with Peg IFN and ribavirin regimen in treatment of chronic hepatitis C
( views:134, downloads:154 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Clinical Infectious Diseases
- Issue:
- 2
- DOI:
- 10.3760/cma.j.issn.1674-2397.2018.02.003
- Key Word:
- 肝炎,丙型,慢性;直接抗病毒药物;达诺瑞韦;三联方案;Hepatitis C,chronic;Direct-acting antiviral agents;Danoprevir;Triple regimen
Abstract： So far, thirty-seven clinical trials of danoprevir in treatment of chronic hepatitis C (CHC)have been completed globally,in which more than 2 600 patients were involved.The clinical trials among Chinese patients with genotype 1 CHC showed that the sustained virologic response(SVR)rate reached to 97.0% after twelve-week treatment of danoprevir combined with PR regimen(Peg IFN and ribavirin), and the safety was good.
- [1]中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南（2015更新版）[J].2015,(12).
- [2]戴明佳,颜学兵.丙型肝炎病毒NS3/4A蛋白酶抑制剂的研究进展[J].2014,(3).
- [3]Edward J. Gane,Regine Rouzier,Catherine Stedman,etc.Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients[J].2011,55(5).
- [4]Guyader D,Marcellin P,Patat A,etc.Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study.[J].2011,54(6).
- [5]Gregory Everson,Curtis Cooper,Christophe Hézode,etc.DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4[J].2015,35(1).
- [6]Jia-Horng, Kao,Min-Lung, Yu,Chi-Yi, Chen,etc.Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.[J].2018,(Spec ).
- [7]Haznedar,J.O.,Blotner,S.,Reddy,M.B.,etc.Impact of low-dose ritonavir on danoprevir pharmacokinetics: Results of computer-based simulations and a clinical drug-drug interaction study[J].2012,51(7).
- [8]Ming-Lung Yu M.D.,Ph.D.,Wan-Long Chuang M.D.,Ph.D..New treatments for HCV: Perspective from Asia[J].2015,5(1).
- [9]Marcellin,P.,Cooper,C.,Balart,L.,etc.Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-na?ve patients with hepatitis c virus genotype 1 infection[J].2013,145(4).
- [10]Beigelman L,Jiang Y,Hong J,etc.Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).[J].2008,52(12).
- [11]Goelzer P.,Morcos P.N.,Tran J.Q.,etc.1180 Ritonavir Substantially Reduces Reactive Metabolite Formation of the Hcv Protease Inhibitor Danoprevir Both in Vitro and in Vivo[J].2012,56.
- [12]Jacobson IM,McHutchison JG,Dusheiko G,etc.Telaprevir for previously untreated chronic hepatitis C virus infection.[J].2011,364(25).
- [13]Tujios S,Fontana RJ.Mechanisms of drug-induced liver injury: from bedside to bench.[J].2011,8(4).
- [14]Yutong Jiang,Steven W. Andrews,Kevin R. Condroski,etc.Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease[J].2014,57(5).
- [15]Poordad F,McCone J Jr,Bacon BR,etc.Boceprevir for untreated chronic HCV genotype 1 infection.[J].2011,364(13).
- [16]Tarik, Asselah,Christophe, Moreno,Christoph, Sarrazin,etc.An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Na?ve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).[J].2016.
- [17]Everson,G.T.,Kiser,J.J.,Burton,J.R..Drug-drug interactions during antiviral therapy for chronic hepatitis C[J].2013,10(10).